openPR Logo
Press release

HPK1 Inhibitors Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

06-02-2025 08:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

HPK1 Inhibitors Pipeline Appears Robust With 8+ Key Pharma

DelveInsight's, "HPK1 inhibitors Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the HPK1 Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPK1 Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the HPK1 Inhibitors Pipeline. Dive into DelveInsight's comprehensive report today! @ HPK1 Inhibitors Pipeline Outlook [https://www.delveinsight.com/sample-request/hpk1-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the HPK1 Inhibitors Pipeline Report

* In May 2025, Treadwell Therapeutics Inc. announced a study will be a first-in-human study evaluating the safety and tolerability of CFI-402411 in subjects with advanced solid malignancies, when CFI-402411 is administered as a single agent or in combination with pembrolizumab. CFI-402411 is an oral pill that blocks the function of HPK1. Blocking HPK1 could stimulate an immune response against the tumor in patients. This immune response could be further enhanced when combined with pembrolizumab. The data obtained from this study will determine the dose and schedule and subject selection for further clinical studies.
* DelveInsight's HPK1 Inhibitors Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for HPK1 Inhibitors treatment.
* The leading HPK1 Inhibitors Companies such as TradeWell Therapeutics, BeiGene, ABM Therapeutics, Nimbus Therapeutics, Arvinas and others.
* Promising HPK1 Inhibitors Pipeline Therapies such as CFI-402411, Pembrolizumab, PRJ1-3024 and others.

Stay ahead with the most recent pipeline outlook for HPK1 Inhibitors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ HPK1 Inhibitors Treatment Drugs [https://www.delveinsight.com/sample-request/hpk1-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

HPK1 Inhibitors Emerging Drugs Profile

* BGB-15025: BeiGene

BGB-15025 is an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor discovered and being developed by BeiGene. HPK1 is a key negative feedback regulator of T-cell receptor signaling, which is believed to play a key role in antitumor immune response. In preclinical studies, the inhibition of HPK1 enhanced T-cell activation, which is expected to enhance the anti-tumor activity of anti-PD-1 inhibitors such as BeiGene's tislelizumab. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of solid tumour.

* CFI-402411: Tradewell Therapeutics

CFI-402411 is a highly potent inhibitor of HPK1, which in preclinical studies has been shown to have an immune-activating effects including the alleviation of inhibition of T cell receptors (TCR), disruption of abnormal cytokine expression, alteration of the tumor immunosuppressive environment through effector cells (i.e. Regulatory T cells or Treg), and potent anti-leukemic effects in several mouse models. TWT-101 is a Phase I/II clinical trial of CFI-402411 in advanced solid malignancies. The study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CFI-402411, as well as to determine optimal dosing as a monotherapy and in combination with the anti-PD1 antibody, pembrolizumab.

* NDI-101150: Nimbus Therapeutics

NDI-101150 is a potent, selective, oral inhibitor of hematopoietic progenitor kinase 1 (HPK1), with a different immunotherapy mechanism to other checkpoint inhibitors. NDI-101150 reactivates anti-tumor activity of T-cells, B-cells and dendritic cells (DCs), even under immunosuppressive conditions. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Solid Tumor.

The HPK1 Inhibitors Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of HPK1 Inhibitors with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPK1 Inhibitors Treatment.
* HPK1 Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* HPK1 Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPK1 Inhibitors market

Explore groundbreaking therapies and clinical trials in the HPK1 Inhibitors Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New HPK1 Inhibitors Drugs [https://www.delveinsight.com/sample-request/hpk1-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

HPK1 Inhibitors Companies

TradeWell Therapeutics, BeiGene, ABM Therapeutics, Nimbus Therapeutics, Arvinas and others.

HPK1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

HPK1 Inhibitors Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Unveil the future of HPK1 Inhibitors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ HPK1 Inhibitors Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hpk1-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the HPK1 Inhibitors Pipeline Report

* Coverage- Global
* HPK1 Inhibitors Companies- TradeWell Therapeutics, BeiGene, ABM Therapeutics, Nimbus Therapeutics, Arvinas and others.
* HPK1 Inhibitors Pipeline Therapies- CFI-402411, Pembrolizumab, PRJ1-3024 and others.
* HPK1 Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HPK1 Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on HPK1 Inhibitors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ HPK1 Inhibitors Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hpk1-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* HPK1 inhibitors: Overview
* Mechanism of action
* Pipeline Therapeutics
* Therapeutic Assessment
* HPK1 inhibitors - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* CFI-402411: Tradewell Therapeutics
* Preclinical Stage Products
* HPK1 (I-O Program): Arvinas
* Drug profiles in the detailed report.....
* Inactive Products
* HPK1 inhibitors - Collaborations Assessment- Licensing / Partnering / Funding
* HPK1 inhibitors - Unmet Needs
* HPK1 inhibitors - Market Drivers and Barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hpk1-inhibitors-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hpk1-inhibitors-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HPK1 Inhibitors Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here

News-ID: 4047702 • Views:

More Releases from ABNewswire

Dry Eye Disease Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Palatin Technologies, Novaliq, mc2 therapeutics
Dry Eye Disease Market Trends Point to Steady Growth Ahead by 2034, DelveInsight …
The Key Dry Eye Disease Companies in the market include - Palatin Technologies, Novaliq, mc2 therapeutics, and others. The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics. DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding
Sharon Winters' Cutted Chicken in Shanghai: A Memoir of Culture, Connection, and Finding Home In The Most Unexpected Place
Sharon Winters' Cutted Chicken in Shanghai: A Memoir of Culture, Connection, and …
Part travelogue, part love letter, Sharon Winters' memoir, Cutted Chicken in Shanghai, captures the humor, heart, and unforgettable adventures of living abroad, exploring culture, and finding friendship in a city that became her second home. Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXcUSnDEgw0nvf5H8gQ5JKqAIwQYLCNTRZJ_yCxIdO0BXgsLKeaKi-tXagC1YO4RBaDh2FFVuoPY_vqQIm69AwJY9ThWHrm_TOyqwbugdyNAthxC5-FqO0iqzQXeBXC2hEOa_mFHmA?key=WndQkMaC4xuBkMMS4ys0zQ Sharon Winters is a retired English and Math teacher, world traveler, humorist, and award-winning author whose writing blends wit, heart, and a love of adventure. A multi-faceted talent with a gift for turning everyday encounters
Viltrox Joins the L-Mount Alliance, Expanding Creative Possibilities
Viltrox Joins the L-Mount Alliance, Expanding Creative Possibilities
Standardized lens mount is already supported by Leica, SIGMA, Pansonic, and more Shenzhen, China - September 3rd, 2025 - Viltrox is proud to announce it has joined the L-Mount Alliance. This reinforces Viltrox's commitment to delivering accessible, high-performance tools for creators, and to advancing the L-Mount standard. This collaboration empowers Viltrox to design L-Mount products that open new creative horizons for both photographers and filmmakers. Viltrox now stands alongside the alliance's founding
Acute Liver Failure Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | RHEACELL, Versantis, Martin Pharmaceuticals, Grifols Therapeutics
Acute Liver Failure Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Liver Failure pipeline constitutes 5+ key companies continuously working towards developing 5+ Acute Liver Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Acute Liver Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also

All 5 Releases


More Releases for HPK1

HPK1 Inhibitors Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "HPK1 inhibitors Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in HPK1 inhibitors pipeline landscape. It covers the HPK1 Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPK1 Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment
HPK1 Inhibitor Market Anticipated to Expand Rapidly During 2024-2034, Says Delve …
DelveInsight's "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034′′ report offers an in-depth understanding of the HPK1 Inhibitor, historical and forecasted epidemiology as well as the HPK1 Inhibitor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the HPK1 Inhibitor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HPK1 Inhibitor Market Forecast https://www.delveinsight.com/sample-request/hpk1-inhibitor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of
HPK1 Inhibitor Drugs Market 2034: FDA, EMA and PDMA Approvals, Epidemiology, Rev …
(Albany, USA) DelveInsight's "HPK1 Inhibitor Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of HPK1 Inhibitor, historical and forecasted epidemiology as well as the HPK1 Inhibitor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. HPK1 Inhibitor companies are BeiGene, Treadwell Therapeutics, Nimbus Therapeutics, Pfizer, Zhuhai Yufan Biotechnologies Co., Ltd., and Others. The HPK1 Inhibitor market report provides current treatment practices,
HPK1 Inhibitor Market Analysis 2032: EMA, PDMA, FDA Approvals, Medication, Clini …
(Albany, USA) DelveInsight's "HPK1 Inhibitor Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of HPK1 Inhibitor, historical and forecasted epidemiology as well as the HPK1 Inhibitor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The HPK1 Inhibitor market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted HPK1 Inhibitor
HPK1 Inhibitor Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, …
HPK1 Inhibitor companies are BeiGene, Treadwell Therapeutics, Nimbus Therapeutics, Pfizer, Zhuhai Yufan Biotechnologies Co., Ltd., and Others. (Albany, USA) DelveInsight's "HPK1 Inhibitor Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of HPK1 Inhibitor, historical and forecasted epidemiology as well as the HPK1 Inhibitor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The HPK1 Inhibitor market report provides current treatment practices, emerging
HPK1 Inhibitor Market is Expected to Expand at a Healthy Growth Rate During the …
The HPK1 Inhibitor Competitive Landscape And Market Forecast report offers an in-depth understanding of the HPK1 Inhibitor, historical and forecasted epidemiology as well as the HPK1 Inhibitor market trends in the 7MM. DelveInsight's "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2032 report offers an in-depth understanding of the HPK1 Inhibitor, historical and forecasted epidemiology as well as the HPK1 Inhibitor market trends in the United States, EU4 (Germany, Spain, Italy,